Fujii, Hideki
4 papers on CoChatORCID 0000-0001-7610-1068
Most cited papers
- Verified
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Harrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 497
- Verified
CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer
Mizukami, Y., Kono, K., Kawaguchi, Y., Akaike, H., Kamimura, K., Sugai, H., & Fujii, H. (2008) · International Journal of Cancer
T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers
Cited by 374
- Verified
Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease
Kono, K., Fujii, H., Nakai, K., Goto, S., Shite, J., Hirata, K.-I., Fukagawa, M., & Nishi, S. (2012) · Kidney International
Coronary Interventions and DiagnosticsCardiac Imaging and Diagnostics
Cited by 66
- Verified
Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes
Kono, K., Sato, E., Naganuma, H., Takahashi, A., Mimura, K., Nukui, H., & Fujii, H. (2004) · Clinical Cancer Research
Immunotherapy and Immune ResponsesHER2/EGFR in Cancer Research
Cited by 59
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free